Rockville, Maryland — September 28, 2026 : The global cardiac resynchronization therapy market is valued at USD 7.7 billion in 2026 and is projected to reach USD 16.5 billion by 2036, advancing at a 7.9% CAGR during the forecast period. Fact.MR analysis indicates an absolute opportunity of USD 8.8 billion through 2036 as heart failure treatment programs, hospital electrophysiology capacity, CRT-D utilization, and remote device follow-up contribute to demand for cardiac resynchronization therapy systems.

Get detailed market forecasts, competitive benchmarking, and pricing trends: 

A major factor supporting market expansion is the continuing need to treat eligible heart failure patients who require ventricular resynchronization, particularly when defibrillation protection is also needed. CRT-D systems combine resynchronization and shock therapy within a single implant, making reliable battery performance, lead support, and post-implant monitoring important considerations for electrophysiology teams and hospital procurement departments. The report also identifies guideline-linked candidate selection as an important influence because CRT implantation depends on factors including ejection fraction, rhythm status, QRS duration, and symptom status.

CRT Defibrillator is projected to remain the leading product category, accounting for 61.8% of the market in 2026. Its position reflects demand for systems capable of providing both pacing and defibrillation support for eligible patients at arrhythmic risk. Hospital is the leading end-use segment with a 63.8% share, reflecting the infrastructure required for implantation, including electrophysiology laboratories, imaging capabilities, specialist teams, and structured follow-up services. By application, Heart Failure Treatment leads with a 68.4% share in 2026 because CRT directly addresses ventricular dyssynchrony in selected heart failure patients.

Country-level growth is led within the report's comparison by the USA, which is projected to expand at an 8.3% CAGR from 2026 to 2036. The country's established cardiac-care network supports implantation, generator replacement, and follow-up activity, while FDA-reviewed CRT-D supply developments contribute to the device landscape. Japan follows with an 8.1% CAGR, supported by population aging and specialist cardiac-care infrastructure capable of managing electrophysiology, imaging, implantation, and device monitoring. The UK is forecast to grow at a 7.8% CAGR, with national rhythm-management audit coverage and referral links between heart failure and electrophysiology services supporting structured care pathways.

Recent regulatory activity also illustrates the product-development environment surrounding the market. The Fact.MR report notes that the U.S. FDA approved Boston Scientific RESONATE CRT-D updates on April 21, 2026. It also records a December 2025 FDA PMA supplement involving an alternate lithium supplier for Medtronic ICD and CRT-D batteries. Such developments reinforce the importance of battery sourcing, device reliability, regulatory compliance, and continued product support in purchasing decisions.

Beyond the three countries highlighted in the title, France is projected to record a 7.2% CAGR, while South Korea and Italy are forecast to grow at 7.1% and 6.3%, respectively. The report attributes country-level differences to variations in aging demographics, reimbursement requirements, hospital capacity, specialist availability, rhythm-management programs, and follow-up infrastructure. These factors create distinct adoption conditions across developed cardiac-care markets.

The competitive landscape includes Medtronic, Boston Scientific, Abbott Laboratories, BIOTRONIK, and MicroPort CRM (MicroPort Scientific Corporation). The report identifies direct CRT-D regulatory activity among leading suppliers, while BIOTRONIK and MicroPort CRM are also expanding their participation in CRT systems and remote monitoring. BIOTRONIK received U.S. FDA approval for Acticor Sky and Rivacor Sky ICD/CRT-D systems in April 2026, while MicroPort CRM expanded SmartView Connect across Europe and Australia in December 2025 for compatible CRT-D remote monitoring.

Unlock 360° insights for strategic decision making and investment planning: 

As CRT adoption develops through 2036, suppliers are expected to remain focused on lead reliability, battery performance, MRI-conditional capabilities, software support, and remote follow-up workflows. Fact.MR's Cardiac Resynchronization Therapy Market report provides detailed analysis across product, end use, application, regional markets, country-level growth, competitive activity, and market drivers and restraints.

Countries chosen: USA, Japan, and UK — selected for their relatively high country CAGRs of 8.3%, 8.1%, and 7.8%, respectively, while ensuring European representation through the UK.

Explore More Related Studies Published by Fact.MR Research

Clean Mouthfeel Protein Alternatives Market

Fat-Reduction Protein Lubricants Market

Organic Low-Methoxyl Pectins Market

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

 - Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com